会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Membrane receptor reagent and assay
    • US06790632B2
    • 2004-09-14
    • US10444390
    • 2003-05-23
    • Stephen Eliot Zweig
    • Stephen Eliot Zweig
    • G01N33543
    • G01N33/54373G01N33/5432
    • A membrane receptor reagent and assay is disclosed in which liposomes are bound to an evanescent wave emitting surface. Membrane receptors on the liposome's fluid lipid bilayer membrane are labeled with a fluorescent or luminescent moiety. These membrane receptors are free to diffuse randomly throughout the liposome surface, and thus tend to redistribute according to externally applied forces. The evanescent wave-emitting surface additionally contains reagents that reversibly bind to the membrane receptors, tending to bring them closer to region of high evanescent wave intensity. Test analytes that disrupt or promote the association between the membrane receptors and the surface reagents act to change the average distance between the membrane receptors and the evanescent wave emitting surface, resulting in a change in the fluorescent or luminescent signal. This reagent and assay system functions with physiologically important membrane receptors such as GPCR receptors, other 7-tm receptors, drug transport proteins, cytochrome P450 membrane proteins and other clinically important membrane components. The reagent and assay methods may be incorporated into microarrays, capillaries, flow cells and other devices, and used for drug discovery, ADMET, and other biomedically important assays.
    • 4. 发明授权
    • Detection apparatus and method for the same
    • 检测装置及其方法
    • US06753189B1
    • 2004-06-22
    • US09325214
    • 1999-06-03
    • Kenji NaraharaToshiyuki Uehara
    • Kenji NaraharaToshiyuki Uehara
    • G01N33543
    • G01N33/558G01N2333/02G01N2333/59Y10S436/81Y10S436/823Y10S436/824
    • A catcher, having an immunological epitope, is fixed to a detection zone of a spreading layer. A marker, capable of easy detection, has an inmmunological epitope. The marker and bispecific antibodies are soluble so that they can move on the spreading layer. The bispecific antibodies include a first bispecific antibody, having specificity for the detectable material in the fluid sample and the marker, and a second bispecific antibody, having specificity for the detectable material in the fluid sample and the catcher. Pore sizes and particle diameters are set so that the reaction product in which the marking elements and the particles are bonded are caught at a catching section. The concentration of the marking elements and the particles are increased to improve detection sensitivity. The result is an inexpensive and simple detection apparatus being highly-sensitive for the immunological detection of a detectable material, without wasting valuable antibodies.
    • 具有免疫表位的捕获器固定在扩散层的检测区上。 能够容易检测的标记物具有无效表位。 标记物和双特异性抗体是可溶的,使得它们可以在扩散层上移动。 双特异性抗体包括对流体样品和标记物中的可检测材料具有特异性的第一双特异性抗体,以及对流体样品和捕获器中的可检测材料具有特异性的第二双特异性抗体。 设定孔径和粒径,使得标记元件和颗粒结合的反应产物被捕获在捕获部分。 标记元件和颗粒的浓度增加以提高检测灵敏度。 结果是廉价且简单的检测装置对于可检测材料的免疫学检测高度敏感,而不浪费有价值的抗体。
    • 6. 发明授权
    • Test device for detecting semen and method of use
    • 检测精液的检测装置及使用方法
    • US06686167B2
    • 2004-02-03
    • US09776493
    • 2001-02-03
    • Padma S. Bagaria
    • Padma S. Bagaria
    • G01N33543
    • G01N33/689G01N33/523G01N33/56966Y10S435/805Y10S435/81Y10S435/97Y10S436/805Y10S436/81
    • A test device (20) for detecting semen includes a strip (22) having an introduction station (24), a test station (26), and a control station (28) disposed in spaced apart relationship. The introduction station (24) has labeled p30 antibodies, the test station (26) has immobilized p30 antibodies, and the control station has immobilized polyclonal antibodies. A test sample (500) is deposited in the introduction station (24). If semen is present in the test sample (500), a colored line will appear at the test station (26) and at the control station (28). If no semen is present in the test sample (500), a colored line will only appear at the control station (28).
    • 用于检测精液的测试装置(20)包括具有引入站(24),测试站(26)和以间隔关系设置的控制站(28)的条带(22)。 引入站(24)标记有p30抗体,测试站(26)具有固定化的p30抗体,并且控制站具有固定的多克隆抗体。 测试样品(500)沉积在引入站(24)中。 如果测试样品(500)中存在精液,则在测试站(26)和控制站(28)处将出现一条有色线。 如果测试样品(500)中没有精液,则彩色线将仅出现在控制站(28)处。
    • 9. 发明授权
    • Method for assaying whole blood for the presence or absence of circulating cancer or other target cell fragments
    • 用于测定全血存在或不存在循环癌或其它靶细胞碎片的方法
    • US06670197B2
    • 2003-12-30
    • US09800344
    • 2001-03-05
    • David L. RimmStephen C. WardlawRobert A. LevinePaul Fiedler
    • David L. RimmStephen C. WardlawRobert A. LevinePaul Fiedler
    • G01N33543
    • G01N15/042G01N33/56972G01N33/57484G01N2015/045
    • This method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence or absence of fragments of target analyte cancer cells which are circulating in blood. The analysis is performed in a sample of centrifuged anticoagulated whole blood. The analysis of the presence or absence of fragments of cancer cells relies on the detection of external or internal binding sites which are known to be present only in or on tumorous cancer cells. Fluorophors with distinct wavelength emissions are coupled with antibodies, or other binding moieties such as complementary nucleotide sequences, which antibodies are directed against the epithelial cell fragment membrane binding sites, such as internal or external surface epitopes on the cell fragments, or internal binding sites on cell organelles; and which nucleotide sequences are complementary to portions of cell fragment RNA and/or DNA. The labled binding agents are humoric or soluble in the blood sample. The labeled fluorometric binding site-specific materials may be coupled to small plastic beads which have a density or specific gravity that is preferably greater than the specific gravity or density of the red blood cells. The target cell fragments are less dense than the red cells, and typically have the same density or specific gravity as the platelets or white blood cells in the blood sample. Any of the labeled beads which couple with target cell analyte fragments will have a density or specific gravity that is less than the red cells in the blood sample. Thus cell fragment/labeled bead couples will gravitate into an area in the centrifuged blood sample which area is somewhere above the centrifuged red cell layer. The detection of the labeled target analyte/particle couples can be performed in situ in the centrifuged blood sample either visually or photometrically.
    • 用于分析血液的方法使得能够在放大下分离,检测,枚举和确认在血液中循环的靶分析物癌细胞的片段的存在或不存在。 在离心的抗凝全血样品中进行分析。 对癌细胞片段的存在或不存在的分析依赖于已知仅存在于肿瘤细胞中或肿瘤细胞中的外部或内部结合位点的检测。 具有不同波长发射的荧光体与抗体或其它结合部分例如互补核苷酸序列偶联,所述抗体针对上皮细胞片段膜结合位点,例如细胞片段上的内部或外部表面表位或内部结合位点 细胞器 哪些核苷酸序列与细胞片段RNA和/或DNA的部分互补。 标记的粘合剂是幽默的或可溶于血液样品。 标记的荧光结合位点特异性材料可以耦合到具有优选大于红细胞的比重或密度的密度或比重的小塑料珠粒。 靶细胞碎片比红细胞密度低,通常具有与血液样品中的血小板或白细胞相同的密度或比重。 与靶细胞分析物片段偶联的任何标记珠粒将具有小于血液样品中红细胞的密度或比重。 因此,细胞碎片/标记的珠子对将被引入离心的血液样品中的该区域位于离心红细胞层上方的区域中。 标记的目标分析物/颗粒对的检测可以在离心的血液样品中在视觉上或光度下原位进行。